Category Archives: Business and Investments

Latest From Business and Investments

Forbes Asks: Should Economists Perform Surgery and Doctors Conduct Economic Policy?

TheHill

Over at Forbes, University of Chicago economist Tomas Philipson has an insightful post analyzing several of the arguments frequently made in recent debates about the price and value of innovative medicines. Philipson argues that physicians are often self-interested as buyers when complaining about drug prices, and often fail to understand the broader economic context in which drug pricing decisions must be made: “Just as you wouldn’t let a financial planner perform cancer surgery, we shouldn’t Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

Sens. Alexander and Burr Release “Innovation for Healthier Americans” Report

lab_tech

Today, Senate HELP Committee Chairman Lamar Alexander (R-Tenn.) and committee member Richard Burr (R-N.C.) released a report on the challenges of ‘getting safe treatments, devices and cures to patients more quickly and effectively.’ Specifically, the report looks at what is and is not working at the Food and Drug Administration and the National Institutes of Health. The report kicks off a major initiative by the Committee to examine challenges with drug and medical device development Read More >

Business and Investments, Health, Public Policy  |  Leave a comment  |  Email This Post

Op-Ed in Forbes on the Threat to Philanthropy

lab_tech02

This week, Howard Husock extols the benefits of venture philanthropy through this Forbes op-ed. In the op-ed, Husock points out that private entities conduct a significant portion of applied research toward new drug development as referenced in this 2008 Manhattan Institute paper, “The Truth About Drug Innovation”, co-authored by two researchers from the Tufts University Center for the Study of Drug Development, and Institute Fellow Benjamin Zycher: “. . .among. . . thirty-five drugs and Read More >

Business and Investments, Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Announcing the BIO/Bloomberg Intelligence: 2015 Biotech Industry Outlook Survey

lab_tech

Click here for the BIO/Bloomberg Intelligence: 2015 Biotech Industry Outlook Survey. Your investment plans and budgets all include growth assumptions and market forecasts. Can you trust them? 2014 was another banner year for biotech IPOs, with 81 companies in our industry going public, an increase of nearly 90 percent over 2013. Now we turn our attention to the year ahead and what we can expect. More blue skies or dark clouds?  M&A surpassing last year Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

Chairman Upton and Rep. DeGette Op-Ed: Can We Find Cures for 7,000 Diseases?

21st Century Cures Act

In a CNN.com op-ed, Energy & Commerce Committee Chairman Fred Upton (R-MI) and Representative Diana DeGette (D-CO) provide highlights of policies that they intend to propose to help get more cures and treatments for the more than 7,000 diseases for which only 500 have cures and treatments. Chairman Upton and Rep. DeGette launched the 21st Century Cures Initiative to identify areas of reform to help ‘close the gap between the science of medicine and the Read More >

Business and Investments, Events, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,